News | Cardiovascular Clinical Studies | March 25, 2022

Study: Women Still Missing from Cardiovascular Clinical Trial Leadership

The study took a broad view of cardiovascular clinical trials conducted from 2010 to 2019 and assessed whether female-led studies varied by funding type and subject.

Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the last decade, the number of female principal investigators (PIs) still falls well below the number of males leading similar heart studies, according to a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

Image credit: Getty Images


March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the last decade, the number of female principal investigators (PIs) still falls well below the number of males leading similar heart studies, according to a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

“I was rather surprised that despite efforts to improve female representation in clinical trial leadership, there was barely an increase in recent years,” said Aashna Suvarna, an undergraduate studying molecular and cellular biology at UC Berkeley in California and a study author. “This confirms how much more work we have to do here.”

The study took a broad view of cardiovascular clinical trials conducted from 2010 to 2019 and assessed whether female-led studies varied by funding type and subject. Overall, the proportion of female PIs did not significantly change over the 10-year period.

For the analysis, Suvarna and team conducted a consecutive review of 620 cardiovascular National Institutes of Health (NIH) and industry or pharmaceutical-funded studies on ClinicalTrials.gov.

Of these, only about 1 in 5 studies (18.4%) were led by a female PI. Compared with their male counterparts, female PIs led fewer drug and device trials—18.9% of new drug research and 9.6% of device trials. Women were more likely to lead “other investigations,” which included behavioral, surgery or rehabilitation studies. Women were also more likely to lead trials funded by the NIH rather than industry sponsors, 28.9% vs. 14.7%, respectively.

The researchers also found a correlation between female-led clinical trials and female patient enrollment. Compared with studies conducted by a male PI, studies with a female PI were associated with a 7% mean higher enrollment of female subjects, with an average of 44.9% female subjects for female-led studies vs. an average of 37.9% female subjects for male-led studies.

“The field of cardiology has long struggled with the inclusion of women in clinical trials as well as the underrepresentation of women in the profession itself,” Suvarna said. “Current clinical trials rely on a majority of male subjects, and the generalization of these results [to women] may be inaccurate. Improving representation of women in trials will yield more meaningful results by significantly improving clinical outcomes.”

Heart disease is one of the leading causes of death among women in the U.S., representing about 1 in 5 deaths, but women often experience heart disease differently than men. For example, women often have atypical heart attack symptoms. In addition to the classic gripping chest pain, women may also present with neck, jaw, shoulder, upper back or abdominal discomfort, shortness of breath, pain in one or both arms, nausea or vomiting, or unusual fatigue, among others.

While there have been government-based initiatives and efforts by the NIH to improve the representation of females in clinical research, there are no standardized efforts in industry to achieve those same goals, Suvarna said. The researchers hope the findings of this study will encourage a renewed effort to increase both female PIs in cardiovascular trials and female patient enrollment.

“At the end of the day, regardless of funding source, whatever we can do to improve representation of women in our trials will translate into more impactful clinical trial results,” Suvarna said. “The association between the sex of the PI and the proportion of females recruited suggest a potential strategy for enrolling more females in clinical trials.”

For more information about clinical trials, visit CardioSmart.org/topics/manage-your-care/clinical-trials.

In 2022, the American College of Cardiology launched Clinical Trials Research: Upping Your Game, a program intended to increase the number of individuals historically underrepresented in cardiology who serve as leaders in cardiovascular clinical trials research, including women, African Americans, Native Americans and Hispanics. For more information, visit ACC.org/CTR2020.

Suvarna will present the study, “Sex of Principal Investigators and Patients in Cardiovascular Clinical Trials,” on Monday, April 4, at 10:30 a.m. ET / 14:30 UTC in Prevention and Health Promotion Moderated Poster Theater 4, Hall C.

For more information: www.acc.org

 

Related Women's Health Content:

Sex Differences in 'Body Clock' May Benefit Women’s Heart Health

Diagnostic Differences in Women’s Heart Health

New Advice Will Help Women with Congenital Heart Defects Navigate Pregnancy

VIDEO: Differences in Cardiac Complications and Presentation Between Men and Women — Interview with Cindy Grines, M.D.

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races

Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women

Marked Increase in Cardiovascular Risk Factors in Women After Preeclampsia

VIDEO: Sex Differences in Diagnosing Heart Disease in Women — Interview with Doreen DeFaria Yeh, M.D.

VIDEO: How to Build a Successful Women’s Heart Center — Interview with Malissa Wood, M.D.

Find more articles on women's heart issues in the Women's Cardiovascular Health channel

Find more ACC22 content here.

Women Less Likely to Receive Life-saving Heart Procedures

Women More Likely to Die After Heart Emergency than Men

Related Content

News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
Subscribe Now